166411-41-2

Upstream product

• 114861-22-2 1,2-O-isopropylidene-α-L-xylofuranose 
• 1576-35-8 toluene-4-sulfonic acid hydrazide 
• 166411-39-8 5-O-benzoyl-1,2-O-isopropylidene-7α-L-xylofuranose 
• 98-88-4 benzoyl chloride 
• 41546-31-0 L-xylose 
• 166411-40-1 5-O-benzoyl-1,2-O-isopropylidene-α-L-erythro-pentofuranose-3-ulose 

Downstream Products

• 166411-42-3 1,2-O-isopropylidene-3-deoxy-3-(p-toluenesulfonylhydrazino)-5-O-benzoyl-α-L-ribofuranose 
• 169823-50-1 Benzoic acid (2R,4S,5S)-4-acetoxy-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethyl ester 
• 255818-76-9 2-isobutyrylamino-6-chloro-9-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)purine 
• 255818-77-0 2-isobutyrylamino-6-chloro-9-(5-O-benzoyl-2,3-dideoxy-2-fluoro-α-L-threo-pentofuranosyl)purine 
• 255818-50-9 5-iodo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)uracil 
• 255818-51-0 5-iodo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-α-L-threo-pentofuranosyl)uracil 
• 255818-56-5 5-iodo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine 
• 186648-63-5 5-fluoro-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)uracil 
• 255818-47-4 5-fluoro-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-α-L-threo-pentofuranosyl)uracil 
• 255818-48-5 5-bromo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)uracil 
• 255818-49-6 5-bromo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-α-L-threo-pentofuranosyl)uracil 
• 255818-54-3 5-fluoro-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine 
• 255818-58-7 5-chloro-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine 
• 255818-55-4 5-bromo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine 

Relevant academic research and scientific papers

Monocyclic L-nucleosides with type 1 cytokine-inducing activity

A series of 1,2,4-triazole L-nucleosides were synthesized and evaluated for their ability to stimulate type i cytokine production by activated human T cells in direct comparison to the known active agent ribavirin. Among the compounds prepared, 1-β-L-ribofuranosyl-1,2,4-triazole-3-carboxamide (5, ICN 17261) was found to be the most uniformly potent compound. Conversion of the 3-carboxamide group of 5 to a carboxamidine functionality resulted in 1-β-L- ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride (10), which induced cytokine levels comparable to 5 for two of the three type 1 cytokines examined. Modification of the carbohydrate moiety of 5 provided compounds of reduced activity. Significantly, ICN 17261 offers interesting immunomodulatory potential for the treatment of diseases where type I cytokines play an important role.

L-nucleoside compounds and application thereof

The invention discloses L-nucleoside compounds having the structure characteristic represented by the formula (I) or pharmaceutically acceptable salts thereof, and belongs to the technical field of pharmaceutical chemistry. The compounds can inhibit the activity of RNA viral polymerase, so the compounds can be used as potential drugs for prevention and treatment of infection of RNA viruses such as HCV, influenza virus, HRV (rhinovirus), RSV, Ebola virus, dengue virus, intestinal virus and the like.

Synthesis of 2',3'-dideoxy-2'-fluoro-L-threo-pentofuranosyl nucleosides as potential antiviral agents

A series of 2',3'-dideoxy-2'-fluoro-L-threo-pentofuranosyl nucleosides has been synthesized as potential antiviral agents. The synthesized compounds were evaluated against HIV-1, HBV, HSV-1, and HSV-2. Among the synthesized analogues, only the cytosine derivative showed moderate antiviral activity against HIV and HBV.